Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
A PhD in Pharmaceutical Sciences, Dr Singh has led global regulatory audits, product validations, and quality systems spanning therapeutic formulations, dietary supplements, and functional foods
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
Subscribe To Our Newsletter & Stay Updated
